Home - Marinus Pharmaceuticals

Mindful Innovation

Marinus is developing ganaxolone to improve the lives of
patients with epilepsy and neuropsychiatric disorders

CNS Solutions

Ganaxolone offers a new mechanism of action and is
designed with selectivity and safety in mind

Offering Continuity of Care

GANAXOLONE

The Right Treatment | The Right Formulation
A Wide Range of Conditions

Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, an extensive safety database, and convenient dosing to improve the lives of patients suffering from drug-resistant seizures and neuropsychiatric disorders.

Press Releases

Marinus Appoints Seth H.Z. Fischer to its Board of Directors

Sep 7, 2016

Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2016 Financial Results

Aug 9, 2016

Results from Phase 2 Exploratory Clinical Study Support Continued Development of Ganaxolone in Fragile X Syndrome

Jun 28, 2016

More Press Releases >

Events

There are no events scheduled at this time.

Clinical Trials

Physicians and patients learn more about ganaxolone and Marinus Pharmaceuticals’ clinical trials here.

View Pipeline >